Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 17,755 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Population Clear all

Conditions: Acute Respiratory Failure, Post-Intensive Care Syndrome
Interventions: Mobile Critical Care Program, Attention Control; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Binge Eating Disorder, Overweight and Obesity
Interventions: Cognitive behavioral therapy, Waitlist; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Physical Therapy: Dependent on Patient's Needs; Behavioral
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Postoperative Quality of Recovery
Interventions: Opioid Free Total Intravenous Anesthesia, Total Intravenous anesthesia with opioid; Combination Product
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Ileus, Gastrointestinal Dysfunction
Interventions: Alvimopan; Drug
Lead sponsor: Scott Steele; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anesthesia, Local
Interventions: AG-920, Proparacaine Ophthalmic; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: Up to 10 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: McAllen, Texas

Conditions: Depression During Pregnancy, Depression, Postpartum
Interventions: IMAGINE; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 16 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Afamelanotide Group 1, Afamelanotide Group 2; Drug
Lead sponsor: Clinuvel Pharmaceuticals Limited; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Venous Ulcer
Interventions: Apligraf, Standard of Care Dressing Group; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Frailty
Interventions: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Placebo, Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs); Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 60 Years to 95 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hematuria
Interventions: Electronic Trigger Microhematuria Alert; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 35 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, HIV Infections
Interventions: telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 11
States / cities: Beverly Hills, California • San Diego, California • San Francisco, California + 8 more

Conditions: Anxiety, Chemotherapy-induced Nausea and Vomiting
Interventions: Essential oils, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions: Betahistine, Placebo Oral Tablet; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 59 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Respiratory Pathogens, Upper Respiratory Tract Illness, Lower Respiratory Tract Illness, Acute Respiratory Infection
Interventions: Results available to provider; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Month to 18 Years
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Adolescent Behavior, Violence in Adolescence, Group, Peer, Violence, Non-accidental, Violence, Sexual, Violence, Physical, Violence, Domestic, Emotional Abuse, Coping Skills, Communication, Personal
Interventions: Expect Respect, Enhanced Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 11 Years to 15 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Mountain Sickness (AMS)
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 853 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anterior Cruciate Ligament Rupture
Interventions: Oxycodone, Placebo oral tablet; Drug
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 40 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Tucker, Georgia

Conditions: Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myopia
Interventions: Low-level Red Light Therapy Device; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 13 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Migraine Prophylaxis
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Huntsville, Alabama • Long Beach, California • San Diego, California + 26 more

Conditions: Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
Interventions: Ad2/HIF-1α/VP16, Saline (Placebo Control); Biological · Other
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more

Conditions: Hypotension During Cesarean Delivery, Spinal Anesthesia
Interventions: Cardiac output monitor data; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Cardiovascular Diseases
Interventions: Diet, Exercise, Environment; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 3,938 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Mobile Critical Care Recovery Program for Acute Respiratory Failure Survivors

Neural Response to Food Stimuli: fMRI Changes Following Cognitive Behavioral Therapy for Binge Eating Disorder

Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)

Opioid Free Anesthesia and Bariatric Surgery

Alvimopan as a Rescue Treatment of Postoperative Ileus

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

IMAGINE: Pilot Trial of a Digital Group Intervention to Prevent Perinatal Depression

Implant Pharmacokinetic and Pharmacodynamic Study

A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

Electronic Triggers: Microhematuria Trigger

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Use of Aromatherapy to Reduce Symptom Burden

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

The RAPID Trial: Assessing Point-of-care Influenza and Other Respiratory Virus Diagnostics

Expect Respect Middle School Randomized Trial

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Are Opioids Needed After ACL Reconstruction

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.

Workplace-Sponsored Program to Reduce Obesity